Alendronate affects cartilage resorption by regulating vascular endothelial growth factor expression in rats

Anatomical Record

Volumn 293, Issue 5, 2010, Pages 786-793

  Kang, J H ^a   Choi, N K ^a   Kang, S J ^b   Yang, S Y ^a   Ko, H M ^a   Jung, J Y ^a   Kim, M S ^a   Koh, J T ^a   Kim, W J ^a   Oh, W M ^a   Kim, B Y ^b   Kim, Sunhun ^a  

^a Chonnam National University   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Alendronate; Cartilage resorption; VEGF

Indexed keywords

ALENDRONIC ACID; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; CELL PROLIFERATION; CHONDROGENESIS; CHONDROLYSIS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; EPIPHYSEAL CARTILAGE; EPIPHYSIS; GENETIC TRANSCRIPTION; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MORPHOLOGY; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; TIBIA; WESTERN BLOTTING;

ALENDRONATE; ANIMALS; ANIMALS, NEWBORN; BLOOD VESSELS; BONE DENSITY CONSERVATION AGENTS; BONE DEVELOPMENT; CHONDROCYTES; DOWN-REGULATION; GROWTH PLATE; HYPERTROPHY; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOGENESIS; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

RATTUS;

EID: 77952650295     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.21092     Document Type: Article

References (32)

1. Alvarez J, Costales L, Serra R, Balbín M, López JM. 2005. Expression patterns of matrix metalloproteinases and vascular endothelial growth factor during epiphyseal ossification. J Bone Miner Res 20:1011-1021. (Pubitemid 40712826)
2. Bluteau G, Julien M, Magne D, Mallein-Gerin F, Weiss P, Daculsi G, Guicheux J. 2007. VEGF and VEGF receptors are differentially expressed in chondrocytes. Bone 40:568-576. (Pubitemid 46201943)
3. Burchardt M, Burchardt T, Chen MW, Shabsigh A, de la Taille A, Buttyan R, Shabsigh R. 1999. Expression of messenger ribonucleic acid splice variants for vascular endothelial growth factor in the penis of adult rats and humans. Biol Reprod 60:398-404. (Pubitemid 29063882)
4. Carlevaro MF, Cermelli S, Cancedda R, Cancedda FD. 2000. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: auto-paracrine role during endochondral bone formation. J Cell Sci 113:59-69. (Pubitemid 30066333)
5. Cetinkaya BO, Keles GC, Ayas B, Gurgor P. 2008. Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats. J Periodontol 79:1950-1961.
6. Da Silva JA, Larbre JP, Seed MP, M, Villaggio B, Scott DL, Willoughby DA. 1994. Sex differences in inflammation induced cartilage damage in rodents. The influence of sex steroids. J Rheumatol 21:330-337. (Pubitemid 24078849)
7. Dai J, Rabie AB. 2007. VEGF: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res 86:937-950.
8. Dvorak HF, Brown LF, Detmar M, Dvorak AM. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039.
9. Evans KD, Lau ST, Oberbauer AM, Martin RB. 2003. Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta. Bone 32:268-274.
10. Evans KD, Oberbauer AM. 2007. Spatiotemporal localization of VEGF-A isoforms in the mouse postnatal growth plate. Anat Rec 291:6-13.
11. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF. 1994. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341-346. (Pubitemid 24181082)
12. Felson DT, Kim, YJ. 2007. The futility of current approaches to chondroprotection. Arthritis Rheum 56:1378-1383.
13. Ferrara N, Houck K, Jakeman L, Leung DW. 1992. Molecular and biological properties of the endothelial growth factor family of proteins. Endocrine Rev 13:18-32.
14. Ferrara N. 1999. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543. (Pubitemid 29426311)
15. Fleish H. 1998. Bisphosphonate: mechanism of action. Endocrinol Rev 19:80-100.
16. Garcia-Ramirez M, Toran N, Andaluz P, Carrascosa A, Audi L. 2000. Vascular endothelial growth factor is expressed in human fetal growth cartilage. J Bone Miner Res 15:534-540. (Pubitemid 30134098)
17. Ishii H, Oota I, Arakawa T, Takuma T. 2002. Differential gene expression of vascular endothelial growth factor isoforms and their receptors in the development of the rat masseter muscle. Arch Oral Biol 47:505-510.
18. Kim MS, Kim JH, Lee MR, Kang JH, Kim HJ, Ko HM, Choi CH, Jung JY, Koh JT, BK Kim, Oh HK, Kim WJ, Lee EJ, Kim SH. 2009a. Effects of alendronate on A Disintegrin And Metalloproteinase with Thrombospondin Motifs (ADAMTS) expression in the developing epiphyseal cartilage in rats. Anat Histol Embryol 38:154-160.
19. Kim MS, Jung SY, Kang JH, Ko HM, Jung JY, Koh JT, Kim WJ, Kim SM, Lee EJ, Kim SH. 2009b. Effects of bisphosphonate on the endochondral bone formation of the mandibular condyle. Anat Histol Embryol 38:321-326.
20. Kimura M, Miyazawa K, Tabuchi M, Maeda H, Kameyama Y, Goto S. 2008. Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice. Calcif Tissue Int 82:137-147.
21. Kyle RA. 2000. The role of bisphosphonates in multiple myeloma. Ann Intern Med 132:734-736.
22. Lehmann HJ, Mouritzen U, Christgau S, Clos PA, Christiansen C. 2002. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen Type II degradation products. Ann Rheum Dis 61:530-533. (Pubitemid 34539098)
23. Moses MA, Sudhalter J, Langer R. 1992. Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol 119:475-482.
24. Murata M, Yudoh K, Masuko K. 2008. The potential role of vascular endothelial growth factor (VEGF) in cartilage: how the angiogenic factor could be involved in the pathogenesis of osteoarthritis? Osteoarthritis Cartilage 16:279-286.
25. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N. 2003. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48:1521-1529. (Pubitemid 36682359)
26. Peterson W, Tsokos M, Pufe T. 2002. Expression of VEGF121 and VEGF165 in hypertrophic chondrocytes of the human growth plate and epiphyseal cartilage. J Anat 201:153-157. (Pubitemid 34947129)
27. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg T. 2000. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60:6001-6007.
28. Rogers MJ, Gorden S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. 2000. Cellular and molecular mechanism of action of bisphosphonates. Cancer 88(Suppl):2961-2978. (Pubitemid 30413179)
29. Rowe DJ, Etre LA, Lovdahl MJ, Pietrzyk DJ. 1999. Relationship between bisphosphonate concentration and osteoclast activity and viability. In Vitro Cell Dev Biol Anim 35:383-388.
30. Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A, Caraglia M, Holen I. 2006. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Rep 15:1351-1357.
31. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes J, Abraham J. 1991. The human gene for vascular endothelial growth factor. J Biol Chem 25:11947-11954.
32. Van Offel JF, Dombrecht EJ, Bridts CH, Schuerwegh AJ, Ebo DG, Stevens WJ, De Clerck LS. 2005. Influence of bisphosphonates on the production of pro-inflammatory cytokines by activated human articular chondrocytes. Cytokine 31:298-304.